New stock news | Binhui Biotech IPO prospectus invalidated

Wuhan BinHui Biological Technology Co., Ltd.-B (referred to as BinHui Bio) submitted its Hong Kong IPO prospectus on September 30, 2025, which expired after 6 months on March 30, 2026. Huatai International, CMB International, and BOCI acted as joint sponsors at the time of submission. The prospectus shows that BinHui Bio is a oncolytic virus therapy biotechnology company dedicated to the discovery, development, and commercialization of innovative cancer immunotherapies. The company aims to address global unmet clinical needs by providing breakthrough oncolytic therapies that surpass standard treatments in terms of efficacy and safety. The work of the company is led by Dr. Liu Binlei, the founder and chairman of the board, who has over 30 years of professional knowledge in the fields of tumor immunology and oncolytic virology. Dr. Liu was a core member of the research and development team for the first oncolytic virus drug approved by the FDA, IMLYGIC (talimogene laherparepvec, or T-VEC), and played a key role in its development.